DrugBiological
Pepinemab clinical trials
Also written VX15/2503 and Anti-SEMA4D Monoclonal Antibody VX15/2503.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 5
Vaccinex Inc. (6) · Emory University (3) · Children's Oncology Group (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Ipilimumab (3) · Nivolumab (3) · Avelumab (1) · Pembrolizumab (1) · Dendritic Cell Vaccine (1) · Trastuzumab (1)
Studies
Open first, then newest update. How each study uses pepinemab is read from its arms, and is right about nine times in ten.
Testing it · 11
- Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast CancerSuspendedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05378464Written as Pepinemab
- VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruitingPhase 1Emory UniversityNCT03690986Written as VX15/2503
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaActive, not recruitingPhase 1Emory UniversityNCT03769155Written as VX15/2503
- Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaActive, not recruitingPhase 1/2Vaccinex Inc.NCT05102721Written as Avelumab and Pepinemab
- Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1/2Vaccinex Inc.NCT04815720Written as pepinemab + pembrolizumab
- SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)CompletedPhase 1/2Vaccinex Inc.NCT04381468Written as Pepinemab
- Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid TumorsCompletedPhase 1/2Children's Oncology GroupNCT03320330Written as Pepinemab
- VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerCompletedPhase 1Emory UniversityNCT03373188Written as Anti-SEMA4D Monoclonal Antibody VX15/2503
- A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of PepiCompletedPhase 2Vaccinex Inc.NCT02481674Written as VX15/2503
- Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MSCompletedPhase 1Vaccinex Inc.NCT01764737Written as VX15/2503
- Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid TumorsCompletedPhase 1Vaccinex Inc.NCT01313065Written as VX15/2503
Given in every arm · 1 — pepinemab is usual care beside what is tested
Codes
What other systems call pepinemab · ClinicalTrials.gg INT001968
- UNII (FDA) BPZ4A29SYEPEPINEMABOne source FDA
- NCI Thesaurus C96222PepinemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BPZ4A29SYE | PEPINEMAB | One source FDA |
| NCI Thesaurus | C96222 | Pepinemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.